Evidence map›Paper›PMID 33536926›Full record

ArticleFrontiers in pharmacology2020

Novel Hybrid CHC from β-carboline and

Jiefei Miao, Chi Meng, Hongmei Wu, Wenpei Shan, Haoran Wang, Changchun Ling, Jinlin Zhang, Tao Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Identification ofEndocrine, metabolic & immune disorders drug targets · 2026
    Article
  2. Review
  3. Oleanolic acid enhanced the anticancer effect of fluorouracil by regulating Ca2+ levels in hepatocellular carcinoma cells.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
    Article
  4. Review
  5. Review
  6. 3-(1,2,3-Triazol-4-yl)-β-Carbolines and 3-(1Pharmaceuticals (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jiefei MiaoThe Affiliated Hospital of Nantong University, Nantong University, Nantong, China.
Chi MengSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, China.
Hongmei WuSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, China.
Wenpei ShanSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, China.
Haoran WangSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, China.
Changchun LingThe Affiliated Hospital of Nantong University, Nantong University, Nantong, China.
Jinlin ZhangThe Affiliated Hospital of Nantong University, Nantong University, Nantong, China.
Tao YangThe Affiliated Hospital of Nantong University, Nantong University, Nantong, China.
Nantong University · CNAffiliated Hospital of Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel hybrid CHC was designed and synthesized by conjugating β-carboline with an important active fragment

Indexed as

antiproliferative activitiesdrug resistancehistone deacetylase (HDAC) inhibitorN-hydroxyacrylamideβ-carboline

Identifiers

PMID33536926
PMCPMC7848139
OpenAlexW3125233292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.